Skip to main content
DiaSorin reaches $55.3M deal to acquire Siemens' ELISA business

DiaSorin has agreed to pay $55.3 million on a debt- and cash-free basis for Siemens Healthineers' microtiter-based ELISA immunodiagnostics business and related intangible and tangible assets. The acquisition, which is expected to close this year, will expand DiaSorin's global commercial presence and provide the company a "significant client base" in Europe, DiaSorin said.

Full Story: